RAPID for CNS (A4106)
Research type
Research Study
Full title
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System
IRAS ID
320849
Contact name
Erlick Pereira
Contact email
Sponsor organisation
Boston Scientific Benelux
Clinicaltrials.gov Identifier
Duration of Study in the UK
6 years, 0 months, 31 days
Research summary
Radiofrequency (RF) ablation has been available as a treatment for a variety of conditions including cardiac, central nervous system (CNS) and pain since the 1950's.
RF ablation is a treatment that uses heat, delivered via a special needle, to create small lesions in tissue that permanently alter the pathway of neurological impulses. A high- frequency electrical current is passed along the needle which then creates an electric field at the tip. The thermal energy is created by molecular movement within the electric field which in turn creates heat to generate a lesion, or a small area of permanent damage, within the tissue around the area where the needle is inserted, forcing disruption of neurological impulses.
RF ablation has been used for decades in the treatment of movement disorders such as Parkinson's Disease, Essential Tremor or tremor from other conditions. Today RF ablation can be very useful in treating more severe symptoms in patients for whom current interventions are not suitable.
This study aims to collect data pertaining to real-world outcomes of receiving RF ablation treatment using a Boston Scientific commercially approved radiofrequency ablation system. The device is used according to the Directions for Use in the Central Nervous System (CNS).REC name
East of England - Cambridge East Research Ethics Committee
REC reference
22/EE/0270
Date of REC Opinion
4 Jan 2023
REC opinion
Further Information Favourable Opinion